🎉 M&A multiples are live!
Check it out!

Hybio Pharmaceutical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Hybio Pharmaceutical and similar public comparables like Suven Pharma, Dishman Carbogen Amics, and Syngene International.

Hybio Pharmaceutical Overview

About Hybio Pharmaceutical

Hybio Pharmaceutical Co Ltd is engaged in manufacturing and sale of peptide products. The company's peptide finished dosage products include digestive system agents, immune modulators, hormone and endocrine modulators, antiviral agents, and hemostatic products. It also provides peptide CRO and CMO services, as well as API products.


Founded

2003

HQ

China
Employees

n/a

Website

hybio.com.cn

Financials

LTM Revenue $106M

LTM EBITDA $60.7M

EV

$1.9B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Hybio Pharmaceutical Financials

Hybio Pharmaceutical has a last 12-month revenue of $106M and a last 12-month EBITDA of $60.7M.

In the most recent fiscal year, Hybio Pharmaceutical achieved revenue of $59.4M and an EBITDA of -$32.4M.

Hybio Pharmaceutical expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Hybio Pharmaceutical valuation multiples based on analyst estimates

Hybio Pharmaceutical P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $59.4M $81.3M XXX XXX XXX
Gross Profit $73.1M $75.0M XXX XXX XXX
Gross Margin 123% 92% XXX XXX XXX
EBITDA -$32.4M $36.0M XXX XXX XXX
EBITDA Margin -54% 44% XXX XXX XXX
Net Profit $4.2M -$51.1M XXX XXX XXX
Net Margin 7% -63% XXX XXX XXX
Net Debt $217M $170M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Hybio Pharmaceutical Stock Performance

As of April 15, 2025, Hybio Pharmaceutical's stock price is CNY 13 (or $2).

Hybio Pharmaceutical has current market cap of CNY 11.9B (or $1.6B), and EV of CNY 13.6B (or $1.9B).

See Hybio Pharmaceutical trading valuation data

Hybio Pharmaceutical Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.9B $1.6B XXX XXX XXX XXX $-0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Hybio Pharmaceutical Valuation Multiples

As of April 15, 2025, Hybio Pharmaceutical has market cap of $1.6B and EV of $1.9B.

Hybio Pharmaceutical's trades at 17.7x LTM EV/Revenue multiple, and 30.8x LTM EBITDA.

Analysts estimate Hybio Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Hybio Pharmaceutical and 10K+ public comps

Hybio Pharmaceutical Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.9B XXX XXX XXX
EV/Revenue 23.0x XXX XXX XXX
EV/EBITDA 52.0x XXX XXX XXX
P/E -65.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Hybio Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Hybio Pharmaceutical Valuation Multiples

Hybio Pharmaceutical's NTM/LTM revenue growth is 72%

Hybio Pharmaceutical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Hybio Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Hybio Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Hybio Pharmaceutical and other 10K+ public comps

Hybio Pharmaceutical Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 37% XXX XXX XXX XXX
EBITDA Margin 44% XXX XXX XXX XXX
EBITDA Growth -211% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 116% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 51% XXX XXX XXX XXX
G&A Expenses to Revenue 7% XXX XXX XXX XXX
R&D Expenses to Revenue 37% XXX XXX XXX XXX
Opex to Revenue 115% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Hybio Pharmaceutical Public Comps

See public comps and valuation multiples for Contract Research & Manufacturing and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Jubilant Pharmova XXX XXX XXX XXX XXX XXX
Biocon XXX XXX XXX XXX XXX XXX
Syngene International XXX XXX XXX XXX XXX XXX
Dishman Carbogen Amics XXX XXX XXX XXX XXX XXX
Suven Pharma XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Hybio Pharmaceutical M&A and Investment Activity

Hybio Pharmaceutical acquired  XXX companies to date.

Last acquisition by Hybio Pharmaceutical was  XXXXXXXX, XXXXX XXXXX XXXXXX . Hybio Pharmaceutical acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Hybio Pharmaceutical

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Hybio Pharmaceutical

When was Hybio Pharmaceutical founded? Hybio Pharmaceutical was founded in 2003.
Where is Hybio Pharmaceutical headquartered? Hybio Pharmaceutical is headquartered in China.
Who is the CEO of Hybio Pharmaceutical? Hybio Pharmaceutical's CEO is Ms. Yu Pinxiang.
Is Hybio Pharmaceutical publicy listed? Yes, Hybio Pharmaceutical is a public company listed on SHE.
What is the stock symbol of Hybio Pharmaceutical? Hybio Pharmaceutical trades under 300199 ticker.
When did Hybio Pharmaceutical go public? Hybio Pharmaceutical went public in 2011.
Who are competitors of Hybio Pharmaceutical? Similar companies to Hybio Pharmaceutical include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics.
What is the current market cap of Hybio Pharmaceutical? Hybio Pharmaceutical's current market cap is $1.6B
What is the current revenue of Hybio Pharmaceutical? Hybio Pharmaceutical's last 12-month revenue is $106M.
What is the current EBITDA of Hybio Pharmaceutical? Hybio Pharmaceutical's last 12-month EBITDA is $60.7M.
What is the current EV/Revenue multiple of Hybio Pharmaceutical? Current revenue multiple of Hybio Pharmaceutical is 17.7x.
What is the current EV/EBITDA multiple of Hybio Pharmaceutical? Current EBITDA multiple of Hybio Pharmaceutical is 30.8x.
What is the current revenue growth of Hybio Pharmaceutical? Hybio Pharmaceutical revenue growth between 2023 and 2024 was 37%.
Is Hybio Pharmaceutical profitable? Yes, Hybio Pharmaceutical is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.